Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Leemann

Showing results (11-20 of 26) with videos related to

Pageof 3
Sort By:
European Journal of Clinical Pharmacology|January 1, 1986
Single-dose quinidine treatment inhibits metoprolol oxidation in extensive metabolizersT Leemann, P Dayer, U A Meyer
Clinical Pharmacokinetics|October 19, 2001
Quantitative drug interactions prediction system (Q-DIPS): a dynamic computer-based method to assist in the choice of clinically relevant in vivo studiesP Bonnabry, J Sievering, T Leemann, et al.
Clinical Pharmacology and Therapeutics|October 1, 1995
In vivo inhibition profile of cytochrome P450TB (CYP2C9) by (+/-)-fluvastatinC Transon, T Leemann, N Vogt, et al.
European Journal of Clinical Pharmacology|August 24, 1999
Quantitative drug interactions prediction system (Q-DIPS): a computer-based prediction and management support system for drug metabolism interactionsP Bonnabry, J Sievering, T Leemann, et al.
Biochemical and Biophysical Research Communications|April 15, 1988
Bioactivation of the narcotic drug codeine in human liver is mediated by the polymorphic monooxygenase catalyzing debrisoquine 4-hydroxylation (cytochrome P-450 dbl/bufI)P Dayer, J Desmeules, T Leemann, et al.
European Journal of Clinical Pharmacology|January 1, 1985
Interindividual variation of beta-adrenoceptor blocking drugs, plasma concentration and effect: influence of genetic status on behaviour of atenolol, bopindolol and metoprololP Dayer, T Leemann, A Marmy, et al.
Schweizerische Medizinische Wochenschrift|December 5, 1987
[In vitro tests of hepatic oxidation in man, predictive of drug interactions]P Dayer, T Leemann, R Striberni, et al.
European Journal of Clinical Pharmacology|January 1, 1985
Effect of oxidative polymorphism (debrisoquine/sparteine type) on hepatic first-pass metabolism of bufuralolP Dayer, L Balant, A Kupfer, et al.
European Journal of Clinical Pharmacology|January 1, 1996
Interindividual variability in catalytic activity and immunoreactivity of three major human liver cytochrome P450 isozymesC Transon, S Lecoeur, T Leemann, et al.
European Journal of Clinical Pharmacology|January 1, 1986
Stereo- and regioselectivity of hepatic oxidation in man--effect of the debrisoquine/sparteine phenotype on bufuralol hydroxylationP Dayer, T Leemann, A Küpfer, et al.
Pageof 3

Showing results (11-20 of 26) with videos related to

Sort By:
Pageof 3
European Journal of Clinical Pharmacology|January 1, 1986
Single-dose quinidine treatment inhibits metoprolol oxidation in extensive metabolizersT Leemann, P Dayer, U A Meyer
Clinical Pharmacokinetics|October 19, 2001
Quantitative drug interactions prediction system (Q-DIPS): a dynamic computer-based method to assist in the choice of clinically relevant in vivo studiesP Bonnabry, J Sievering, T Leemann, et al.
Clinical Pharmacology and Therapeutics|October 1, 1995
In vivo inhibition profile of cytochrome P450TB (CYP2C9) by (+/-)-fluvastatinC Transon, T Leemann, N Vogt, et al.
European Journal of Clinical Pharmacology|August 24, 1999
Quantitative drug interactions prediction system (Q-DIPS): a computer-based prediction and management support system for drug metabolism interactionsP Bonnabry, J Sievering, T Leemann, et al.
Biochemical and Biophysical Research Communications|April 15, 1988
Bioactivation of the narcotic drug codeine in human liver is mediated by the polymorphic monooxygenase catalyzing debrisoquine 4-hydroxylation (cytochrome P-450 dbl/bufI)P Dayer, J Desmeules, T Leemann, et al.
European Journal of Clinical Pharmacology|January 1, 1985
Interindividual variation of beta-adrenoceptor blocking drugs, plasma concentration and effect: influence of genetic status on behaviour of atenolol, bopindolol and metoprololP Dayer, T Leemann, A Marmy, et al.
Schweizerische Medizinische Wochenschrift|December 5, 1987
[In vitro tests of hepatic oxidation in man, predictive of drug interactions]P Dayer, T Leemann, R Striberni, et al.
European Journal of Clinical Pharmacology|January 1, 1985
Effect of oxidative polymorphism (debrisoquine/sparteine type) on hepatic first-pass metabolism of bufuralolP Dayer, L Balant, A Kupfer, et al.
European Journal of Clinical Pharmacology|January 1, 1996
Interindividual variability in catalytic activity and immunoreactivity of three major human liver cytochrome P450 isozymesC Transon, S Lecoeur, T Leemann, et al.
European Journal of Clinical Pharmacology|January 1, 1986
Stereo- and regioselectivity of hepatic oxidation in man--effect of the debrisoquine/sparteine phenotype on bufuralol hydroxylationP Dayer, T Leemann, A Küpfer, et al.
Pageof 3